



Vascular Embolization: Present and Future

Guest Editor:

Prof. Dr. Romaric Loffroy

Department of Vascular,
Oncologic and Interventional
Radiology, University of Dijon
School of Medicine, Bocage
Teaching Hospital, 14 Rue
Gaffarel, BP 77908, CEDEX, 21079
Dijon, France

Deadline for manuscript
submissions:

closed (30 April 2024)

Message from the Guest Editor

Transcatheter endovascular embolization has gained acceptance over the last two decades as a minimally invasive therapeutic approach compared to surgery. Embolization is routinely used worldwide in the field of oncology and vascular diseases, alone or in combination with other treatments, in several indications, such as tumor devascularization, aneurysms, bleedings or emergencies to occlude vessels and treat patients. The use of embolization in clinical practice has exploded in recent years and requires a thorough understanding of the behavior (rheology and vascular topology) and biocompatibility of each agent. To improve the accuracy of targeting, we need new, more sophisticated, bioactive agents, which are currently being developed. This Special Issue aims to publish original and/or review articles covering the state of the art of embolization techniques and occluding agents, and future perspectives of targeted endovascular embolic materials in the field of interventional radiology. Clinical and preclinical or experimental studies are all welcome.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research

Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA

2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)